Company: UPC
Filing Date: 2025-03-03
Form Type: 6-K
Source: 0001213900-25-019406
Chunk: 0

Company: Universe Pharmaceuticals INC
Filing Date: 2025-03-03
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2025

Commission file number: 001-40231

Universe Pharmaceuticals INC

265 Jingjiu Avenue

Jinggangshan Economic and Technological Development Zone

Ji’an, Jiangxi, China 343100

+86-0796-8403309

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒
Form 40-F ☐</div>

Adjournment of Extraordinary General Meeting

On March 1, 2025, Universe
Pharmaceuticals INC (the “Company”) convened an extraordinary general meeting of shareholders (the “March 2025 Extraordinary
General Meeting”). However, due to lack of quorum, the March 2025 Extraordinary General Meeting was adjourned to March 8, 2025,
at 10:00 a.m., Beijing Time at 265 Jingjiu Avenue, Jinggangshan Economy and Technology Development Zone, Ji’an City, Jiangxi 343100,
the People’s Republic of China.

<div align='center'>1

SIGNATURES</div>

Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.

| Date: March 3, 2025 | Universe Pharmaceuticals INC. 
 By:                           | /s/ Gang Lai            |
|:--------------------|:------------------------------|:------------------------|
|                     |                               | Gang Lai                |
|                     |                               | Chief Executive Officer |

<div align='center'>2</div>